reference/1960579

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1960579

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
issn	2051-1426
issueIdentifier	2
pageRange	e000891-
publicationName	Journal for ImmunoTherapy of Cancer
startingPage	e000891
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_75d638fd83a251155694cc3fcf19609e http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f44e02fcf9fa27484f2fa88838529c69 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577
bibliographicCitation	Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy P, Hammers HJ, George S, Grünwald V, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm M, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 Jul;8(2):e000891. doi: 10.1136/jitc-2020-000891.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b0c59bf3b35c2c71c16b6a8c49570692 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3870415ba8c14f987b01abcdd7ea2974 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5329d01956a0ee435472a7dc26d6e7be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_97ee4dbdef022f181ce941a60af415f8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1e1b89dcdaef73da2f7dc38c6ce9a81c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_58b76236fc33365b621c5b84a4b980c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c13318d7e19fd6d0575c318fb6d6f90f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e9db98c12a357d027f2911f865dc2243 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_69ab16809df3c3fa1a23510f6f97ca28 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ec5aa33f969abf9ff95be6e77ca2062e http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9201-3217 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78ae610722bf91452a39e0921913c3d0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b8d4c469b440a3ac9e3c5dab8a75dfa3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_91d88e89d419ba385cfbcb17e24e2398 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_081cc10a9f2c4acf789d4a348a2c7d57 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0217-5261 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_46cd9fad76fa59a3b62a23509f482df7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79f2b2efc8b734097ecfdbd47375be9c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f05e6114edb076757d780a171d4547d1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d78981379ecece16bdb15f5c0ba41b6b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_957226029467759b84354248e5fefc58 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_123daac1bed7e4ddd22b3ea6688349ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6925-2327 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0e03f2b7b4052512ce7a3b2f128c2c3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2c74ce727bd4bfe8a3cd64253491de01 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab74cb0e03cfbde09c96d1c01f9f1f98 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1cc78ff9cf3f9f3f7ecd363db39165f2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83ecfd5848740372f4129a767a84ef19 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_416f6a3b48486dcda8729f323c29c72c http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8449-863X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c82b5b16761dcf99be3286eaf54321b
date	202007
identifier	https://doi.org/10.1136/jitc-2020-000891 https://pubmed.ncbi.nlm.nih.gov/32661118 https://pubmed.ncbi.nlm.nih.gov/PMC7359377
isPartOf	https://portal.issn.org/resource/ISSN/2051-1426 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/41915
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
discusses	http://id.nlm.nih.gov/mesh/M0448793 http://id.nlm.nih.gov/mesh/M000626138 http://id.nlm.nih.gov/mesh/M0585694
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D002292Q000188 http://id.nlm.nih.gov/mesh/D007680Q000188 http://id.nlm.nih.gov/mesh/D000077210Q000627 http://id.nlm.nih.gov/mesh/D000074324Q000627 http://id.nlm.nih.gov/mesh/D000077594Q000627 http://id.nlm.nih.gov/mesh/D000971Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000077210Q000494 http://id.nlm.nih.gov/mesh/D002292Q000401 http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D007680Q000473 http://id.nlm.nih.gov/mesh/D000074324Q000494 http://id.nlm.nih.gov/mesh/D000077594Q000494 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D007680Q000401 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D000971Q000494 http://id.nlm.nih.gov/mesh/D002292Q000473
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5329102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7170

Showing number of triples: 1 to 76 of 76.